Advanced pudafensine into a Phase IIa trial for vulvodynia and expanded the FSD program, supported by a successful rights issue raising SEK 48.3 million. Q2 2025 saw reduced losses and lower R&D spend, with funding secured well into 2027 for ongoing clinical development.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.